Scholarlink

Background <p>Immunocompromised women with autoimmune and inflammatory rheumatic diseases (AIIRDs) are at increased risk of human papillomavirus (HPV) infection and cervical intraepithelial neoplasia, necessitating appropriate cervical cancer screening (CCS). However, there are still limited reports on CCS practices in patients with AIIRD. We assessed the proportion of women with AIIRDs undergoing CCS in accordance with current European guidelines, and factors associated with appropriate or inappropriate screening.</p> Methods <p>We conducted a cross-sectional study at Bordeaux University Hospital (July 2023–July 2024). Women ≥ 18 years with confirmed AIIRDs (systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, Sharp’s syndrome, rheumatoid arthritis, or spondyloarthritis) completed a standardized self-administered questionnaire on rheumatologic and gynaecologic follow-up, CCS practices, and knowledge about HPV/CCS.</p> Results <p>Of the 309 participants included, 302 provided the date of their last CCS. Of these, 120 were classified as high risk for cervical pathology (receiving targeted therapies or immunosuppressive treatment), and 182 as lower risk. Overall, 188 of 302 women (62.3%) reported undergoing CCS in accordance with current guidelines. However, among high-risk patients, 45 of 120 (37.5%) had received a cervical smear within the past year. Inadequate screening was significantly associated with a low level of education, more frequent rheumatologic follow-up, and limited knowledge of cervical pathology. Notably, 16% of participants reported not knowing the purpose of the cervical smear.</p> Conclusion <p>Women with AIIRDs may benefit from increased CCS awareness among rheumatologists and improved patient education by gynaecologist to promote screening. Further studies are needed to characterise disease- and treatment-specific risks more accurately, establish appropriate screening intervals, and optimise CCS practices for women with AIIRDs.</p> Trial registration <p>The study was registered on ClinicalTrials.gov (NCT05961267, date of registration 2023-07-17).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月25日

查看全文
  • Charlotte Delattre,
  • Mayalen Uthurriague,
  • Thomas Barnetche,
  • Marie Lambert,
  • Nadia Mehsen-Cetre,
  • Estibaliz Lazaro,
  • Marie-Elise Truchetet,
  • Claude Hocké,
  • Christophe Richez,
  • Valérie Bernard

摘要

Background

Immunocompromised women with autoimmune and inflammatory rheumatic diseases (AIIRDs) are at increased risk of human papillomavirus (HPV) infection and cervical intraepithelial neoplasia, necessitating appropriate cervical cancer screening (CCS). However, there are still limited reports on CCS practices in patients with AIIRD. We assessed the proportion of women with AIIRDs undergoing CCS in accordance with current European guidelines, and factors associated with appropriate or inappropriate screening.

Methods

We conducted a cross-sectional study at Bordeaux University Hospital (July 2023–July 2024). Women ≥ 18 years with confirmed AIIRDs (systemic lupus erythematosus, systemic sclerosis, Sjögren’s syndrome, Sharp’s syndrome, rheumatoid arthritis, or spondyloarthritis) completed a standardized self-administered questionnaire on rheumatologic and gynaecologic follow-up, CCS practices, and knowledge about HPV/CCS.

Results

Of the 309 participants included, 302 provided the date of their last CCS. Of these, 120 were classified as high risk for cervical pathology (receiving targeted therapies or immunosuppressive treatment), and 182 as lower risk. Overall, 188 of 302 women (62.3%) reported undergoing CCS in accordance with current guidelines. However, among high-risk patients, 45 of 120 (37.5%) had received a cervical smear within the past year. Inadequate screening was significantly associated with a low level of education, more frequent rheumatologic follow-up, and limited knowledge of cervical pathology. Notably, 16% of participants reported not knowing the purpose of the cervical smear.

Conclusion

Women with AIIRDs may benefit from increased CCS awareness among rheumatologists and improved patient education by gynaecologist to promote screening. Further studies are needed to characterise disease- and treatment-specific risks more accurately, establish appropriate screening intervals, and optimise CCS practices for women with AIIRDs.

Trial registration

The study was registered on ClinicalTrials.gov (NCT05961267, date of registration 2023-07-17).